D. Galdermans
University of Antwerp
30 Papers
253 Citations
D. Galdermans is an academic researcher from University of Antwerp. The author has contributed to research in topics: non-small cell lung cancer (NSCLC) & Erlotinib. The author has an hindex of 12, co-authored 29 publications.
Chat about Author
Papers
Paclitaxel for malignant pleural mesothelioma: a phase II study of the EORTC Lung Cancer Cooperative Group.
J. Van Meerbeeck,C. Debruyne,N. van Zandwijk,Pe Postmus,M.C. Pennucci,F.J.M. van Breukelen,D. Galdermans,H. Groen,P. Pinson,M. van Glabbeke,E. Van Marck,G. Giaccone +11 more
TL;DR: In conclusion, paclitaxel at the dose and schedule investigated in this trial had no major activity in the treatment of malignant pleural mesothelioma.
82
Changing preferences for information and participation in the last phase of life: a longitudinal study among newly diagnosed advanced lung cancer patients
Koen Pardon,Reginald Deschepper,R. Vander Stichele,R. Vander Stichele,Jan L. Bernheim,Freddy Mortier,Freddy Mortier,Nathalie Bossuyt,Denis Schallier,Paul Germonpré,D. Galdermans,W. Van Kerckhoven,Luc Deliens,Luc Deliens +13 more
TL;DR: Pain seemed to be a trigger for patients wanting more involvement, which contrasts with studies suggesting that patients who are more ill tend to give up more control.
30
A phase II EORTC study of temozolomide in patients with malignant pleural mesothelioma.
J.P. van Meerbeeck,Paul Baas,C. Debruyne,Egbert F. Smit,R. J. van Klaveren,D. Galdermans,Ma. Lentz,Christian Manegold,Giuseppe Giaccone +8 more
TL;DR: Oral temozolomide is an inactive agent in malignant mesothelioma, and symptom assessment showed no improvement and an increase of pain was observed during the study.
27
Second primary lung cancer in Flanders: frequency, clinical presentation, treatment and prognosis.
J. Van Meerbeeck,Joost Weyler,A. Thibaut,Johan Vansteenkiste,J. Aumann,Georges Deneffe,D. Galdermans,M. Haelterman,Gustaaf Joos,M. Noppen,P. Pinson,J. Tasson,A Van den Eeckhout,M. Uydebrouck +13 more
TL;DR: It is concluded that the occurrence of a second primary lung cancer can not be predicted based on patient or tumour characteristics and that only surgical retreatment offers a chance of long survival in these patients.
27